Discovery Series – Advanced Peptide Therapy – Sermorelin

Presented by Travis Gerhart, DC

Every provider has patients quietly frustrated by the same cluster of complaints: stubborn body composition, poor sleep, slower recovery, waning energy, thinning skin. Most of the time, the story underneath is somatopause — the age-related decline in growth hormone that begins in a patient’s 30s. In this Discovery Series session, Travis Gerhart, DC makes the clinical case for Sermorelin and shows you exactly how to bring it into your practice.

Travis opens with the science: how the GH-IGF-1 axis actually works, why declining pulsatile GH release drives so many of the symptoms your patients describe, and why sermorelin — as a growth hormone-releasing hormone analog — is a safer, more physiologic choice than synthetic HGH. You’ll leave understanding the mechanism well enough to explain it to a skeptical patient in plain English.

From there, the session becomes an operational playbook. Travis walks through BMI-based dosing (200–500 mcg SC nightly), the four-phase monitoring cadence, the IGF-1 and IGFBP-3 biomarkers that matter, and the absolute and relative contraindications that determine who is — and who is not — a candidate. He also covers what patients realistically feel at 30 days, 90 days, and 6 months so your team can set expectations correctly at intake.

If sermorelin is a program you’ve considered but never quite launched, this session gives you the confidence and the clinical structure to say yes the next time a patient asks about growth hormone.

This presentation is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Compounded medications are not FDA-approved and may differ from FDA-approved products in safety, quality, or effectiveness. All clinical decisions remain the sole responsibility of the prescribing healthcare provider. Individual results may vary.